In the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction @ ( TRITON-TIMI @ ) , prasugrel reduced the primary ischaemic endpoint as compared with clopidogrel in acute coronary syndrome ( ACS ) patients planned to undergo percutaneous coronary interventions , but increased the risk of bleeding .